Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
On the other hand, corrected calcium levels did not predict any outcome (HR per 1 mg/dL 0.83; 95% CI 0.57 to 1.21).Results of univariable and multivariable Cox models.VariablesUnivariable Cox proportional modelMultivariable Cox proportional modelHazard ratio95% CIP valueHazard Ratio95% CIP valueAge, years1.010.99 to 1.020.490.990.97 to 1.010.36Male sex0.830.56 to 1.240.371.170.71 to 1.910.54eGFR, mL/min/1.73m20.950.93 to 0.97 < 0.010.990.97 to 1.010.33Urine protein: refref1 + 3.482.19 to 5.53 < 0.012.851.72 to 4.74 < 0.012 to 3 + 6.023.27 to 11.1 < 0.013.541.74 to 7.18 < 0.01Corrected calcium, mg/dL0.830.57 to 1.210.331.130.74 to 1.740.56Phosphate, mg/dL2.491.90 to 3.25 < 0.011.601.14 to 2.230.0125D, 10 ng/mL0.710.51 to 0-970.030.800.54 to 1.190.271.25D, 10 pg/mL0.680.59 to 0.79 < 0.010.820.68 to 0.990.04Log intact PTH1.791.30 to 2.48 < 0.011.601.19 to 2.14 < 0.01Log intact FGF231.641.35 to 1.99 < 0.010.990.74 to 1.340.97Active vitamin D compounds1.270.85 to 1.890.240.910.55 to 1.490.70Living donor0.840.50 to 1.420.520.990.52 to 1.890.97Donor age, year1.000.98 to 1.010.721.000.98 to 1.020.77Log transplant vintage1.551.18 to 2.03 < 0.011.300.95 to 1.770.1095% CI 95% confidence interval; GFR estimated glomerular filtration rate; 25D 25-hydroxyvitamin D; 1,25D 1,25-dihydroxyvitamin D; PTH parathyroid hormone; FGF23 fibroblast growth factor 23.
Source: MBD parameters and renal outcome. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cohort study.
Cohort study
Examines exposures and outcomes over time within a defined group.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
We conducted a prospective long-term follow-up cohort study included 263 KTRs with grafts functioning at least 1 year after transplantation.
Source: Abstract.
Patients were regularly followed up (monthly) at the outpatient clinic until the end of observation (March 31, 2018), lost to follow-up, or dead.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Serum phosphate levels modify the impact of parathyroid hormone levels on renal outcomes in kidney transplant recipients
Cohort study · Scientific Reports · 2020
Original publication title
Serum phosphate levels modify the impact of parathyroid hormone levels on renal outcomes in kidney transplant recipients
© The Author(s) 2020
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Separate assessment of mineral bone disorder (MBD) parameters including calcium, phosphate, parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D (1,25D) predict renal outcomes in kidney transplant recipients (KTRs), with conflicting results. To date, data simultaneously evaluating these parameters and interwoven relations on renal outcomes are scarce. We conducted a prospective long-term follow-up cohort study included 263 KTRs with grafts functioning at least 1 year after transplantation. The outcome was a composite of estimated GFR halving and graft loss.
Cox regression analyses were employed to evaluate associations between a panel of six MBD parameters and renal outcomes. The outcome occurred in 98 KTRs during a median follow-up of 10.7 years. In a multivariate Cox analysis, intact PTH (iPTH), phosphate, and 1,25D levels were associated with the outcome (hazard ratio, 1.60 per log scale; 95% confidence interval, 1.19 to 2.14, 1.60 per mg/dL; 1.14 to 2.23 and 0.82 per 10 pg/mL; 0.68 to 0.99, respectively). Competing risk analysis with death as a competing event yielded a similar result.
After stratification into four groups by iPTH and phosphate medians, high risks associated with high iPTH was not observed in KTRs with low phosphate levels (P-interaction < 0.1). Only KTRs not receiving active vitamin D, poor 1,25D status predicted the worse outcome (P-interaction < 0.1). High iPTH, phosphate, and low 1,25D, but not FGF23, levels predicted poor renal outcomes. Simultaneous evaluation of PTH and phosphate levels may provide additional information regarding renal allograft prognosis.
Authors’ abstract
Separate assessment of mineral bone disorder (MBD) parameters including calcium, phosphate, parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D (1,25D) predict renal outcomes in kidney transplant recipients (KTRs), with conflicting results. To date, data simultaneously evaluating these parameters and interwoven relations on renal outcomes are scarce. We conducted a prospective long-term follow-up cohort study included 263 KTRs with grafts functioning at least 1 year after transplantation. The outcome was a composite of estimated GFR halving and graft loss.
Cox regression analyses were employed to evaluate associations between a panel of six MBD parameters and renal outcomes. The outcome occurred in 98 KTRs during a median follow-up of 10.7 years. In a multivariate Cox analysis, intact PTH (iPTH), phosphate, and 1,25D levels were associated with the outcome (hazard ratio, 1.60 per log scale; 95% confidence interval, 1.19 to 2.14, 1.60 per mg/dL; 1.14 to 2.23 and 0.82 per 10 pg/mL; 0.68 to 0.99, respectively). Competing risk analysis with death as a competing event yielded a similar result.
After stratification into four groups by iPTH and phosphate medians, high risks associated with high iPTH was not observed in KTRs with low phosphate levels (P-interaction < 0.1). Only KTRs not receiving active vitamin D, poor 1,25D status predicted the worse outcome (P-interaction < 0.1). High iPTH, phosphate, and low 1,25D, but not FGF23, levels predicted poor renal outcomes. Simultaneous evaluation of PTH and phosphate levels may provide additional information regarding renal allograft prognosis.
Publication and source details
Original title: Serum phosphate levels modify the impact of parathyroid hormone levels on renal outcomes in kidney transplant recipients
Yohei Doi; Takayuki Hamano; Naotsugu Ichimaru; Kodo Tomida; Yoshitsugu Obi; Naohiko Fujii; Satoshi Yamaguchi; Tatsufumi Oka; Yusuke Sakaguchi; Isao Matsui; Jun-ya Kaimori; Toyofumi Abe; Ryoichi Imamura; Shiro Takahara; Yoshiharu Tsubakihara; Norio Nonomura; Yoshitaka Isaka
Scientific Reports · 2020
© The Author(s) 2020https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T16:42:52.299840+00:00
DOI: 10.1038/s41598-020-70709-4 · PMC7426845